期刊
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
卷 19, 期 4, 页码 672-675出版社
AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2007090981
关键词
-
资金
- NCI NIH HHS [CA-114000, CA-40035] Funding Source: Medline
- PHS HHS [U54-126505] Funding Source: Medline
It is now 20 years since the tumor-associated factor parathyroid hormone-related peptide was identified. Since then, there have been significant changes in the understanding of the hypercalcemic syndromes associated with malignancy and with the role of this peptide in normal physiology as well as this specialized pathologic setting. Parathyroid hormone-related peptide has become a useful diagnostic tool in the differential diagnosis of hypercalcemia, and approaches to inhibit its expression or its effects by malignant cells hold promise for treating the hypercalcemia and osteolysis associated with some cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据